To receive daily emails from Breaking Christian News to your inbox CLICK HERE
Israel Starts Clinical Trial of Antibody COVID Vaccine: 3 Patients Already Able to Leave Hospital"We are encouraged by the results of the product neutralization activity and we believe our product has the potential to be an effective treatment for hospitalized, non-ventilated COVID-19 patients with pneumonia, and look forward to the results from this trial." -Amir London, Kamada's CEO [ISRAEL21c.org] Physicians at Hadassah University Medical Center in Jerusalem report promising early results of a clinical study in which they are treating Covid-19 patients with immunoglobulin (IgG) derived from the plasma of recovered patients found to have high levels of antibodies. (Screengrab image: via Kamada) The serum is prepared by Rehovot-based biopharmaceutical company Kamada. Three patients have already received the serum and are doing well, according to Dr. Yaron Ilan, chief of internal medicine at Hadassah University Medical Center. "The first patient demonstrated a rapid clinical benefit and went home after previously being in moderate condition." The other two also have been released from the hospital. Ilan stressed that this experimental treatment, though very encouraging, is in an early phase. Dr. Zeev Rotstein, director general of Hadassah Medical Center, called their recovery "almost a miracle." Rotstein was among the initiators of the collection of plasma from recovered corona patients. He also revealed to the Jerusalem Post on August 12 that Hadassah will help test a Russian-developed vaccine for coronavirus. For the past three months, Hadassah has been collecting plasma donations from recovered patients with the cooperation of ultra-Orthodox communal organizations. Kamada said additional Israeli hospitals are taking part in this Phase 1/2 clinical trial of the anti-SARS-CoV-2 plasma-derived IgG. "This open-label, single-arm multicenter study was approved by the Ministry of Health in Israel. The trial will assess the safety, pharmacokinetics and pharmacodynamics of the company's plasma-derived IgG product in hospitalized, non-ventilated Covid-19 patients with pneumonia," Kamada reported. "A total of 12 eligible patients will be enrolled and receive Kamada's product at a single dose of 4g within 10 days of initial symptoms. Patients will be followed for 84 days. In parallel, Kamada intends to further explore the potential of its IgG product to prevent Covid-19 disease in healthy subjects at risk in a separate study." This milestone is part of the global collaboration agreement established in April 2020 between Kamada and its partner Kedrion Biopharma for the development, manufacturing and distribution of a plasma-derived immunoglobulin product as a potential treatment for coronavirus disease. Kamada and Kedrion intend to conduct a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration soon in anticipation of obtaining FDA approval of the proposed clinical development program. Meanwhile, Kedrion will collect Covid-19 convalescent plasma from recovered American patients. "We are encouraged by the results of the product neutralization activity and we believe our product has the potential to be an effective treatment for hospitalized, non-ventilated COVID-19 patients with pneumonia, and look forward to the results from this trial," said Amir London, Kamada's CEO. Subscribe for free to Breaking Christian News here
To receive daily emails from Breaking Christian News to your inbox CLICK HERE Other Recent Articles from Breaking Christian News Trump Under Fire for Endorsing the Bible, Urging Americans to Pray Speaker Johnson Announces He'll Invite Netanyahu to Address Congress Federal Appeals Court Rules Pennsylvania Must Only Count Mail Ballots With Dates, Signatures President Trump to Join Wake Honoring Slain NYPD Officer, While Biden Attends Fundraiser Elon Musk to Pay Embattled Doctor's Legal Fees after Speaking Out against COVID Lockdowns Safety of Women Hangs in Balance after Oral Arguments on Abortion Pill Regulation New Federal Gun Grab Law Would Criminalize Shooting Ranges, and Even Private Security Treasury Sec. Yellen: Biden Has NO Plan to Save Social Security Chick-fil-A Abandons Long-Held 'No Antibiotics' Pledge on Chicken The War in Myanmar: Karenni Resistance Fighters Ask for Prayer and Practical Help The World Is Facing a Major Population Crisis by 2075 If Birth Rates Keep Falling FDA Admits COVID Vaccines Cause Seizures in Toddlers Kamala Harris Won't Disclose Why Biden Campaign Is Active on TikTok Despite Security Worries Search the Articles Archives |
All articles on this site and emails from BCN are copyrighted property of Breaking Christian News. Permission is given to link to, or share a BCN story if proper attribution is given to both the original writer and summarizer of the story. Breaking Christian News 2005-2019. All Rights Reserved.
Breaking Christian News is a division of Elijah List Publications, Inc. All Rights Reserved
Disclaimer: Articles and links, as well as the source articles linked to; do not necessarily reflect the opinion of Breaking Christian News.
Home | Store | Subscribe | Facebook | Article Archive |